header logo image


Page 11234..»

Archive for April, 2019

Ethical, Legal and Social Implications Research Program …

Tuesday, April 30th, 2019

NIH is institutinga number ofchanges tohow it categorizes clinical trial research.Many ELSI studiesthat previously were not considered clinical trials will now be categorized as such and will be subject to new application, review and reporting requirements.Please visit theClinical Trials definition websitefor guidance indetermininghow your study will be categorized. If you have any questions or concerns, please contact ourELSIprogram directors

ELSI applications that do not involve a clinical trial can still be submitted under the ELSI R01, R21 and R03 program announcements listed below.

ELSI applicationsthat are determined to involve a clinical trial cannot be submitted under these announcements and must now besubmitted under either the NIHParent R01--Clinical Trial Required(PA-18-345)or the NIHParent R21--Clinical Trial Required (PA-18-344)program announcements.When submitting these applications, researchers shoulduse thePHS Assignment Request Formtorequest thatNHGRI (and any other relevant Institutes or Centers) be assigned the grant, andtorequest study section review assignment to theContinuous Special Emphasis Panel on Societal and Ethical Issues in Research Study Section(ZRG1 SEIR).

The NHGRI, along with several other National Institutes of Health (NIH) institutes, has released revised general program announcements to solicit research projects that anticipate, analyze, and address the ethical, legal, and social implications of the discovery of new genetic technologies and the availability and use of genetic information resulting from human genetics and genomic research.

The NHGRI ELSI Program accepts Conference Grant (R13) applications. For specific instructions for preparing a conference grant application, see:

The ELSI program participates in a number of training and career development funding opportunities.

The Fogarty International Center'sinternational bioethics training programs[fic.nih.gov] support education and research training to develop ethics expertise in low- and middle-income countries (LMICs). The programs complement other global health research and research training programs in the mission areas of NIH Institutes and Centers.

PA-16-288:Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)Expiration Date: September 30, 2019

PA-16-289:Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)Expiration Date: September 30, 2019

Read more:
Ethical, Legal and Social Implications Research Program ...

Read More...

Russia Opens the Door for Stem Cell Clinical Trials | BioSpace

Tuesday, April 30th, 2019

Stem Cell Global Boom

The widespread global outreach potential of stem cell therapies is becoming apparent, especially given the recent news of a second person going into long-term remission (some saying cured) of HIV after undergoing a stem cell transplant. Regenerative medicine is becoming a powerful instrument for providing cures to previously incurable diseases. According to a recent statement, the US FDA expects to receive over 200 investigational new drug (IND) applications per year by 2020, many of which include cell and gene therapies. In fact, the FDA estimates that 10 to 20 new cell and gene therapy products per year will be approved by 2025. The number of stem cell trials carried out globally has also been growing exponentially, having over 7000 trials registered on ClinicalTrials.gov with 16 FDA-approved cellular and gene therapies.

The Official Launch of Biomedical Cell Products (BCP) in Russia

While the US, Europe and some Asian countries have had a fully functional, comprehensive regulatory platform for BCP procedures for over two decades, Russia is relatively new to the area, only recently approving a regulatory framework. 2018 marked a key breakthrough for the Russian market and the global pharmaceutical arena, when the Russian government enacted a law involving amendments to biomedical cell product guidelines, which officially opened the door for Russia to enter the stem cell technologies industry. The regulation stipulates and defines what a BCP is, specifying that both registered medical products and pharmaceuticals can be classified as BCPs.

When speaking about the current pharma industry landscape, the major development of the past several years is, without doubt, the creation and implementation of stem cell product regulation and related clinical trial procedures," Dmitry Goryachev, head of Expertise and Control of Ready Medicaments at the FSBI Russian Ministry of Health Scientific Centre for Expert Evaluation of Medicinal Products, noted during the 6th annual OCT Conference on Clinical Trials.

Although cellular biomedicines show great promise, there are some important scientific and practical nuances to note, such as patent rights, certification procedures, and BCP costs. Experts from the I. M. Sechenov Institute for Regenerative Medicine claim that one of the key challenges for biomedical stem cell production in Russia lies in the absence of suitable production sites, with an estimated cost of building such infrastructure as high as USD 7 million.

Alexey Martynov, Director of the Stem Cell Products Manufacturer Association, added that with the stem cell industry on the rise, there is an exponentially growing demand for trained professionals in the field, therefore relevant courses are being included in the universities curriculum for students as well as professionals. There are also a few widescale government programs which stimulate the emergence of new medical products and innovative technology in healthcare. One such program is aimed at developing stem cell technologies.

The Russian Federation government has recently issued specific decrees which outline the stem cell technologies development strategy for 2018-2020. This program undertakes the development of knowledge sharing centers, both from the product development and production points of view, as well as medical center accreditations for them to be eligible for such studies, Vadim Merkulov, Deputy Director of the Russian Ministry of Health Scientific Centre for Expert Evaluation of Medicinal Products, elaborated.

According to the previously mentioned BCP procedure law, the number of accredited entities eligible to accommodate stem cell clinical trials will grow from 5 in 2018 to 20 in 2019 then up to 50 in 2020. The budget for BCP production, called production capacity, is also estimated to reach USD 230 million by 2020, up from USD 180 million in 2018. This strategy will stimulate and potentially boost stem cell studies in Russia, ultimately resulting in increased patient access to stem cell therapies.

Russian Market Potential for Stem Cell Studies

The Russian pharmaceutical and healthcare markets have a lot of potential for stem cell studies and clinical trials in general. Key strengths of the region include fast patient enrollment, large clinical trial participation and favorable currency exchange rates. Fast patient enrollment is especially essential for early-stage trials to allow for faster project initiation. Some US and European corporations might be cautious to enter the market because of language barriers or logistic issues. However, these concerns can be avoided by choosing a reputable CRO with experience

It is high time for the biomedicine and stem cell industry in our country to enter the phase when it is possible to grow and develop within the regulatory framework. Understanding the registration procedures and a solid regulatory platform, without doubt, create a very favorable environment to launch progressive stem cell studies in Russia, commented Dmitry Sharov, president of OCT, a CRO located in Russia and Eastern Europe. In the upcoming years, we will witness a giant leap in the development of new treatment methods.

The first uptick in medical product applications is already being seen as the first licensing application for a cartilage restoration BCP was filed in February. Despite the fact that this technology has been in development since 2016, it is just now possible to apply for a license as the new bill is being implemented.

About OCT

OCT is a leading full-service CRO serving Russia and Eastern Europe. OCT offers a full range of services to manage Phase 1-4 and BE studies, as well as offering standalone services, such as medical writing, consulting, project management and monitoring, and data management and biostatistics. More information can be found on their website.

This article was provided by OCT and modified by Chelsea for clarity.

View original post here:
Russia Opens the Door for Stem Cell Clinical Trials | BioSpace

Read More...

Gene Therapy : Homology Medicines

Tuesday, April 30th, 2019

Homology Medicines gene therapy approach utilizes our proprietary AAVHSC vectors to deliver a functional gene to a cell where there is a missing or mutated gene. Once delivered, the functional gene may lead to therapeutic protein expression. With gene therapy, the genes do not integrate into the genome so this approach can be curative in slow- or non-dividing cells (e.g., adult liver or central nervous system).

Our gene therapy construct includes a functional copy of the gene and a promotor sequence that is designed to enable the gene to be turned on in the cell and ultimately transcribed to express a therapeutic protein without integrating into the genome.

Our unique vectors have demonstrated significant systemic biodistribution to multiple tissue types in preclinical studies, including liver, central nervous system (CNS), muscle (skeletal and cardiac) and eye*. This enables us to potentially address a broad range of monogenic diseases.

Our lead development program is an AAVHSC-mediated gene therapy treatment for adults with the rare disease phenylketonuria. Learn more about our pipeline and therapeutic focus.

*Homology data on file; Ellsworth JL, Smith LJ, Rubin H, et al. Widespread transduction of the central nervous system following systemic delivery of AAVHSC17 in non-human primates. American Society of Gene & Cell Therapy Annual Meeting. May 2017.

Read more from the original source:
Gene Therapy : Homology Medicines

Read More...

Integrative Medicine Of NYC | Top Integrative Medicine …

Tuesday, April 30th, 2019

Mary-Laura Klesaris MD

Dr. Mary-Laura Klesaris is a compassionate and energetic Integrative Medicine Doctor at Integrative Medicine of NYC,who takes a multidimensial, evidence based approach to medicine with a focus on bioidentical hormone therapy and seeks to treat the root cause of physical and emotional health issues, including anxiety, depression, insomnia, headaches, menopause, weight gain and chronic fatigue/pain. She is committed to cultivating strong relationships with her patients and collaborates with each patient to help them attain their health and wellness goals.

In addition to nineteen years of experience in internal medicine as well as extensive post-graduate training in age management, Dr. Klesaris completed a fellowship in bio-identical hormone replacement therapy with Dr. Sangeeta Pati, whose distinguished Sajune Institute for Restorative and Regenerative Medicine in Orlando, Florida, is among the most acclaimed centers in the country practicing restorative medicine. Her Five Point Restorative approach includes VortexHealing sessions from practitioner, Susan Hwang, and consultation with a functional nutritionist.

Dr. Klesaris is completing her fellowship in regenerative medicine through the American Academy of Age Management Medicine (A4M). She graduated from St. Georges University School of Medicine and was appointed Chief Medical Resident at the Mt. SinaiCabrini Hospital program in New York City.

Note: sees patients age 18 and older.

Interests:

Bioidentical Hormone Replacement Therapy

Exercise, Nutrition, Weight Management

Lifestyle Modification

Preventive Health and Education

Stress Management

See the article here:
Integrative Medicine Of NYC | Top Integrative Medicine ...

Read More...

Integrative Medicine | Long Island, New York | Oasis Medicine

Tuesday, April 30th, 2019

my passion is to empower and transform you, to go beyond disease, pain and suffering and find your true vitality! Dr. DAve

common Conditions we treat

Click on icons to learn more...

Autoimmune Disease

HormonalImbalances

Lyme Disease/Tick-borne Ilness

Neurodegenerative Disorders

Obesity/Metabolics

Pain/Inflammation

~ Dr. Dave & The Oasis Family

WHAT OUR PATIENTS ARE SAYING ABOUT US...

Dr. Dave really spends time with me in my weight loss battle!

He really has helped me lower my cholesterol and lose weight.

I am very happy with my progress and he knows how to change things to boost my metabolism. He really has solutions for every plateauI hit.

LORRAINE V.

Dr. Dave is experienced, talented and honest!

I have been seeing Dr. Dave for the last 5 years and he has cured many of my illnesses, such as tremors, generalized anxiety, sleep disorders and weight management.

His professionalism and caring manner cannot be matched.

P.B.

I've dealt with alignment issues that result in pain on the right side of my body, lower back and knee. As someone who runs and leads a fit lifestyle, its hard to find healthy solutions to pain. Its been a pleasure to work through all the different ways I can help improve my workouts andoverall body pain.

VANESSA L.

popular Services

Medical Cannabis

DNA Testing

Pain Management

Weight Loss

Brain Wellness

Age Management

2019Dr. Dave's Food & Wellness, LLC.All Rights Reserved.

Statements on this site have not been evaluated by the Food and Drug Administration

More:
Integrative Medicine | Long Island, New York | Oasis Medicine

Read More...

Genomics and Medicine | NHGRI

Tuesday, April 30th, 2019

It has often been estimated that it takes, on average, 17years to translate a novel research finding into routine clinical practice. This time lag is due to a combination of factors, including the need to validate research findings, the fact that clinical trials are complex and take time to conduct and then analyze, and because disseminating information and educating healthcare workers about a new advance is not an overnight process.

Once sufficient evidence has been generated to demonstrate a benefit to patients, or "clinical utility," professional societies and clinical standards groups will use that evidence to determine whether to incorporate the new test into clinical practice guidelines. This determination will also factor in any potential ethical and legal issues, as well economic factors such as cost-benefit ratios.

The NHGRIGenomic Medicine Working Group(GMWG) has been gathering expert stakeholders in a series of genomic medicine meetingsto discuss issues surrounding the adoption of genomic medicine. Particularly, the GMWG draws expertise from researchers at the cutting edge of this new medical toolset, with the aim of better informing future translational research at NHGRI. Additionally the working group provides guidance to theNational Advisory Council on Human Genome Research (NACHGR)and NHGRI in other areas of genomic medicine implementation, such as outlining infrastructural needs for adoption of genomic medicine, identifying related efforts for future collaborations, and reviewing progress overall in genomic medicine implementation.

Read the original here:
Genomics and Medicine | NHGRI

Read More...

Whole Body MRI Human Longevity, Inc.

Tuesday, April 30th, 2019

Sure, medical centers across the country have magnetic resonance imaging, or MRI, machines. But what makes the Health Nucleus MRI different?

First, in traditional medical care, its nearly impossible to get access to a whole body MRI without a significant medical reason. If you injure your knee, only your knee will be scanned in a standard medical MRI, for fear something else in the rest of the body may be seen or not seen and therefore opening the health system up for serious liability concerns.

At the Health Nucleus, we partner with you to take control of your health by actively enrolling in a whole body MRI, and we are equipped to review and interpret your entire scan to generate an unprecedented snapshot of your current health.

Protocols Not Available Anywhere Else

Without the use of contrast media that leaves many feeling nauseous, but whose purpose is to illuminate differences in the body, our MRIs secret sauce is found in our post-processing analysis.

Our proprietary software uncovers cancer, neurological, metabolic and cardiovascular concerns at their earliest stages when they can be addressed.

And unlike traditional medical care, our Health Nucleus is prides itself on a spa-like setting whose luxuries are on the level of our pioneering science. Our MRI techs take pride in ensuring your comfort and calmness in our MRI with guided meditation, aroma therapy, and audio-visual distraction should you wish.

Challenge your perspective on health. Learn how our Health Nucleus MRI might impact you and your health.

See the article here:
Whole Body MRI Human Longevity, Inc.

Read More...

Journal of Nanomedicine and Biotherapeutic Discovery- Open …

Tuesday, April 30th, 2019

Nanomedicine is an application of nanotechnology which made its debut with greatly increased possibilities in the field of medicine. Nanomedicine desires to deliver research tools and clinically reformative devices in the near future.

Journal of Nanomedicine & Biotherapeutic Discovery is a scholarly open access journal publishing articles amalgamating broad range of fields of novel nano-medicine field with life sciences. Nanomedicine & Biotherapeutic Discovery is an international, peer-reviewed journal providing an opportunity to researchers and scientist to explore the advanced and latest research developments in the field of nanoscience & nanotechnology.

This is the best academic journal which focuses on the use nanotechnology in diagnostics and therapeutics; pharmacodynamics and pharmacokinetics of nanomedicine, drug delivery systems throughout the biomedical field, biotherapies used in diseases treatment including immune system-targeted therapies, hormonal therapies to the most advanced gene therapy and DNA repair enzyme inhibitor therapy. The journal also includes the nanoparticles, bioavailability, biodistribution of nanomedicines; delivery; imaging; diagnostics; improved therapeutics; innovative biomaterials; regenerative medicine; public health; toxicology; point of care monitoring; nutrition; nanomedical devices; prosthetics; biomimetics and bioinformatics.

The journal includes a wide range of fields in its discipline to create a platform for the authors to make their contribution towards the journal and the editorial office promises a peer review process for the submitted manuscripts for the quality of publishing. Biotherapeutics journals impact factors is mainly calculated based on the number of articles that undergo single blind peer review process by competent Editorial Board so as to ensure excellence, essence of the work and number of citations received for the same published articles.

The journal is using Editorial Manager System for quality peer review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Journal of Nanomedicine & Biotherapeutic Discovery or outside experts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.

Submit manuscript at http://editorialmanager.com/chemistryjournals/ or send as an e-mail attachment to the Editorial Office at[emailprotected]

More here:
Journal of Nanomedicine and Biotherapeutic Discovery- Open ...

Read More...

Top 10 Destinations for Stem Cell Therapy – PlacidWay

Monday, April 29th, 2019

Top 10 Destinations for Stem Cell Therapy

Stem Cell Therapy has made tremendous progress over the past decade. The years of approved clinical trials have shown that stem cell therapy works for certain conditions. Patients should understand that although stem cell therapy can do wonders for some diseases and illnesses, it is not for everything and everyone.

Before choosing to undergo stem cell therapy patients should undergo a thorough research about the viability of the treatment in a certain country. Unfortunately, there are many clinics which state that they are accredited and that their treatment is approved, only to attract patients and money. Stem cell therapy can be categorized into:

1. Clinically-proven stem cell therapy

Such a clinical trial program costs millions of dollars, therefore only a few accredited institutions and centers had the possibility to undergo such programs.

2. Non-approved stem cell therapy in accredited centers

Competent physicians working in accredited centers can offer non-approved stem cell therapies, as long as the patient is informed about the risks and the lack of scientific support.

3. Fraudulent stem cell therapy

Stem cell therapy can be offered by clinics with no accreditation and by physicians with questionable competency. They are the ones who do exaggerated promotional claims about the efficacy and safety of the stem cell therapy, which has no scientific backing.

Studies made so far suggest that stem cells have the potential of developing into different types of cells and so repair the tissue and organs affected by various medical conditions. There are hundreds of different stem cells in our bodies, which are formed at different times in our lives and with different purposes. The embryonic stem cells are found only in the early stages of development, while adult stem cells develop and remain in our bodies the entire life.

Stem cell therapy gives hope where mainstream medical science fails to offer results. So far, the most common stem cell therapy is blood stem cell transplantation for conditions and diseases of the blood, the immune system or to restore the blood after treatments for certain cancer types. Some injuries or diseases of the bone, cornea or skin can be treated using grafted tissue which depends on stem cells from these parts of the body. But people should understand that like any other type of treatment, stem cell therapy can have side effects, and these can vary from individual to individual.

As people will try anything to see at least a slight improvement in their health or their dear ones, more and more are flocking to other countries and to clinics which promote safe and successful stem cell therapy for a multitude of serious conditions. Stem Cell Tourism, as it is called, is in a continuous expansion as patients want to try the promising therapy. But which are the best destinations for stem cell therapy?

South Korea has made tremendous progress in stem cell research, thanks to the country's flexible policies in this matter. Scientists have been able to develop stem cells which genetically match patients of all genders, ages, and races, which means that they can produce stem cells that fit each individual's needs and with a lower risk of rejection. South Korea might soon get to the forefront of stem cell research.

Singapore, also considered Asia's stem cell center, has more than 40 stem cell research centers. Over the years the country has attracted top scientists from all over the world, offering them a host of incentives and the authorization to use embryos for research. This has helped the country to become one of the top stem cell destinations.

China, world famous for its acupuncture and traditional Chinese medicine, plans to become a leader in stem cell research and development. In 2012, the Ministry of Health and the Ministry of Science started to evaluate all stem cell centers that were functioning illegally. This is of utmost importance for future medical tourists who will seek approved and safe stem cell therapy in China.

Stem Cell clinics: Beike Biotech, ReLife International Medical Center

It has been years since patients from the US and Canada have started choosing this destination to get stem cell therapy for serious medical conditions such as paralysis, autism or cerebral palsy. Mexico continues to make tremendous progress in this area and provide safe stem cell therapy.

Stem Cell clinics: Progencell-Stem Cell Therapies

Germany continues to attract patients coming from all over the world for stem cell therapy. The country is known as Europe's Stem Cell hub, thanks to the tremendous progress made in the Adult Stem Cell research and development.

Stem Cell clinics: Anova IRM Medical Center

Stem Cell therapy in Ukraine has helped hundreds of patients suffering from cirrhosis, pancreatic necrosis, burn disease, hepatitis, diabetes, critical lower limb ischemia and multiple sclerosis. The positive results of the therapy, continue to attract international patients.

Stem cell clinics: EmCell Clinic, Unique Cell Treatment Clinic

Austria is another destination preferred by medical tourists for stem cell therapy. Stem cell therapy in Austria has offered a chance to a normal life to patients suffering from Diabetes, Eye Diseases, Neurological Diseases, Gonarthritis or Peripheral vascular disease.

Stem Cell clinics: Stem Cell Therapy Center Vienna

After the US, Turkey has the highest number of JCI accredited healthcare institutions in the world. Turkey is fast-tracking stem cell research and development with new approaches being tested by renowned scientists and physicians. Patientsfrom Europe, Asia, and the Middle East come here to take advantage of the benefits offered by stem cell therapy.

Stem Cell clinics: Leading International Vision LIV Hospitals

Another stem cell therapy leader in Asia is Thailand, a country which, for the past few years has taken stem cell research to the next level by producing cardiac muscle from human embryonic stem cells, successfully using adult stem cells to treat arthritis and discovering a method to extract stem cells from a human amniotic fluid.

Although stem cell therapy might seem for many the last hope, we advise those who begin this journey to look for and seek help from specialists in this type of medical procedure. Experts will help you choose a safe medical destination and a high-quality hospital. Most of all you must understand that stem cell therapy can help some patients, but never cures them.

Being informed and doing a thorough research about what destination, clinic, and doctor to choose is a must when taking such a decision. Get as much information as you can about the center where you plan to undergo the treatment, try to get real patients testimonials, clinical data evaluation, find out about the centers' and doctors' credentials, detailed evaluation of the procedure they use, what methods and types of stem cells they provide, the real cost of the treatment with all expenditures included (airplane, accommodation, meals, hospital and other fees, etc).

By getting informed you will feel more secure, andtraveling abroad for medical carewill be a positive life-changing experience.

PlacidWay can offer you all the information you need for a successful medical experience overseas. Contact us and get more information about any Stem Cell Therapy on our website.Do not hesitate to contact us!

Disclaimer

Stem Cell Therapy is still an experimental treatment. Any information related to Stem Cell Therapy provided on this website is for educational purposes only. It is not intended to either replace a consultation with a licensed physician or be construed as medical advice or any emergency health need you may be experiencing.

Continued here:
Top 10 Destinations for Stem Cell Therapy - PlacidWay

Read More...

National Blindness Professional Certification Board

Friday, April 26th, 2019

The National Blindness Professional Certification Board (NBPCB) was created to certify qualified specialists in work with the blind. At present, the Certification Board oversees four certifications - the National Orientation and Mobility Certification (NOMC), the National Certification in Rehabilitation Teaching for the Blind (NCRTB), the National Certification in Literary Braille (NCLB), and the National Certification in Unified English Braille (NCUEB).

The National Orientation and Mobility Certification (NOMC) emphasizes nonvisual instruction, and Structured Discovery Cane Travel .

The National Certification in Rehabilitation Teaching for the Blind (NCRTB) emphasizes nonvisual instruction through Structured Discovery Rehabilitation Teaching methods and principles.

The National Certification in Literary Braille (NCLB) is specifically intended for teachers working with blind children or adults. All those who are certified will hold valid certification until their expiration date; however, it is no longer offered and has been replaced with the NCUEB.

The National certification in Unified English Braille (NCUEB) is specifically intended for professionals working with blind children or adults.

The NBPCB has also developed an approval process for orientation training centers who utilize Structured Discovery methodology throughout their programs and a consumer-focused approach.

Subscribe to the O&M Announcement List

Subscribe to the Braille Announcement list

For details regarding how to schedule any of our certification exams in your area, please contact us atadmin@nbpcb.org.

Go here to read the rest:
National Blindness Professional Certification Board

Read More...

What Is Regenerative Medicine? – Pain Doctor

Friday, April 26th, 2019

One of the most promising and rapidly developing areas in the treatment of pain is regenerative medicine. These treatments helpthe body heal or rebuild itself. While, the body can naturally heal many types of injuries, newer techniques, such as stem cell therapy, may enhance the bodys ability to heal. But, what is regenerative medicine and how does it work?

Regenerative medicine uses cutting-edge therapies to help the body replace, re-engineer, or regenerate human cells, tissues, or organs that were damaged or injured. The most common applications of regenerative medicine are in new organ growth orrepair and cellular therapies. These both use a patients own cells to stimulate repair tissue and improve function.

The AABB reports that up to one in three people in the U.S. could benefit from regenerative medicine.

Patients with osteoarthritis of the hips and knees can use PRP therapies to stimulate the bodys own healing processes and reduce inflammation. Stem cell therapy could be used to revitalize worn-out intervertebral discs.In the very near future, patients could benefit from lab-grown bladder or heart transplants. These transplants would be derived from the patients very own cells to reduce the risk of transplant rejection or infection.

Regenerative medicine began when the first bone marrow and solid organ transplants were done decades ago. The first successful kidney transplant was in 1954. Successful liver, pancreas, and heart transplants took place in the 60s. From this perspective, regenerative medicine is a fairly established medical practice.

From there, regenerative medicine arose as atruly a cross-disciplinary approach to healthcare. As UPMC notes:

Regenerative medicine is a new field that brings together experts in biology, chemistry, computer science, engineering, genetics, medicine, robotics, and other fields to find solutions to some of the most challenging medical problems faced by humankind.

In the following TED talk, Alan Russell talks a bit aboutthe history of regenerative medicine andwhy so many healthcare professionals are excited about its potential uses.

There are three main types of regenerative therapy, as ARMI explains:

While scientists are working on new types of regenerative medicine that can actually create new body parts from a patients own cells and tissues, this research is still in its infancy. Regenerative medicine for self-repair and cellular therapy, however, is performed on patients today.

Regenerative cellular and self-repair therapies use the following processes:

When an embryo is developing in the womb, it starts out as a mass of stem cells. As the embryo grows, the stem cells multiply and become the specialized cells that make up a body.

Stem cells are body cells that have the potential to become the cells for many types of bodily tissues. Human embryos are a widely recognized and controversial source of stem cells, but stem cells can also be found in the body tissues of adults, such as bone marrow and blood as well as placental tissue. Other adult cells (e.g., skin cells) can be modified through the injection of specific genes or molecules to become stem cells. The various sources of stem cells often have different properties. They are generally capable of becoming some, but not all, types of cells.

Various treatments that involve the extraction of stem cells and their injection into damaged tissues have been developed. Some of these treatments involve taking a persons own stem cells and injecting them into a site of injury. Other treatments rely on stem cells from adult donors. Bone marrow is perhaps the most commonly-accessed source of adult stem cells for regenerative therapies. However, harvesting stem cells from bone marrow is still a surgical procedure requiring anesthesia or sedation.

Though medical research on these treatments is progressing, stem cell treatments are generally considered experimental. They are only approved in the United States as a part of clinical trials. These treatments hold great promise because they may be able to treat certain conditions, such as discogenic back pain, that are difficult to effectively relieve with other methods.

This video from Mayo Clinic gives a quick primer on stem cells.

Another regenerative medicine treatmentis called platelet rich plasma (PRP) therapy. This technique was developed in the 1970s and has been adopted in a variety of medical practices, such as orthopedic surgery, plastic surgery and sports medicine. This treatment gained wider recognition after a number of professional athletes were reported to use it to aid in their recoveries.

PRP therapy involves drawing a small volume of blood from the patient and spinning this blood in a centrifuge. This separates the blood into different layers, each containing concentrated amounts of the substances naturally found in blood: serum in the top layer, white blood cells and platelets in the middle layer, and red blood cells in the bottom layer.

The middle layer, known as PRP concentrate, is then separated from the rest of the blood. This PRP concentrate contains three to five times the normal concentration of the platelets and growth factors that are used in the bodys own healing process. This PRP concentrate is then injected back into the patients body at the site of their injury, for example, into the site of an injured tendon or ligament. This process is then repeated over the course of weeks with additional PRP concentrate being drawn and injected each time.

The platelets injected release hundreds of different proteins involved in the regeneration of tissues. Though research on this treatment continues, the existing research has shown increased healing of several different types of body tissues. Because the patient is injected only with concentrate from their own blood, PRP therapy avoids safety issues of ensuring donor compatibility when using blood and tissue donation.

A pain doctor from Arizona explains how platelet-rich plasma therapy works. You can also find out more about PRP therapy in our posts on the subject.

The process for acquiring the cells for regenerative therapy is different for each type, but the application of the therapy is a simple, straight-forward process no matter the cell type.

The acquisition of adult stem cells typically requires surgery. Amniotic cells come from the amniotic membrane of the placenta, so a placenta is required. This can be a patients own placenta thats been saved, or it can be from a family member. Immediate family members are more likely to be a close-enough match to ensure the cells wont be rejected.

Platelet-rich plasma requires a blood draw. A patients blood is spun in a centrifuge to separate the platelets. The concentrated platelets are combined with residual blood, and the resultant compound is injected into the painful location on the body. From beginning to end, the process of drawing and preparing the blood and injecting the platelet-rich plasma takes between one and two hours.

After the regenerative cells have been injected, the patient is usually able to go home immediately. While physicians often suggest avoiding any strenuous activity for a few days, its possible to go back to regular day-to-day activities right away. Some irritation, soreness, bruising, or other minor discomforts might be present for a few days, but generally there are few side effects of regenerative therapy.

The injected regenerative cells should stimulate the healing and the growth of new tissue. For instance, in degenerative conditions like osteoarthritis, this may mean the growth of new cartilage around joints. With torn muscles or ligaments, regenerative therapy should support the growth of new tissues to heal the injury.

Chronic pain is often the after-effect of degeneration, injury, or illness. Part of the body is left damaged somehow, and that damage causes pain. Most pain therapies concentrate on controlling the pain with medications, injections, or devices that block pain signals in one way or another.

Regenerative therapies are well-suited to treating musculoskeletal pain, or pain thats caused by something in the muscles or bones. Conditions that can respond well to regenerative therapies include:

Compared to other chronic pain therapies, regenerativemedicine has an extremely low risk of side effects.

Regenerative therapies typically involve nothing more than an injection to the painful area of the body, making them very safe. Because the injected compound, whether its stem cells, amniotic cells, or platelet-rich plasma, is usually from the patients own body to begin with, theres almost no risk of infection.

Additionally, one of the biggest risks in the transplant of biological materials, such as organ transplants, is rejection. This is when the body realizes that the transplanted material is foreign and attacks it. However, since the cells used in regenerative therapy are the patients own natural cells, there is no chance at all of rejection.

Stem cell therapy utilizing adult stem cells from the bone marrow is the exception. The harvesting process requires a surgical procedure, which carries the same risks as any other surgery. If, however, the procured stem cells are used on the same person theyre from, this still has the benefit of being extremely low-risk for infection, with no risk of rejection.

It often takes at least two weeks to notice any difference in pain after regenerative therapy, although in some people it may take even longer. In some cases, there may be no discernable pain reduction after regenerative therapy. However, because of its low risk of side effects, it may still be worth discussing this treatment option with a physician.

Regenerative medicine is already available today, in many different applications. According to the NIH:

Naturealso keeps a running list of the scholarly articles about current regenerative medicine research and trials.

As to wide-spread availability of these therapies, that depends. Since stem cell and regenerative medicine is still in its infancy, many insurance providers dont cover the cost of these procedures. That means many procedures are paid out of pocket. You may find discounted optionsby reaching out to pain clinics and independent medical groups who are performing their own studies and patient trials onregenerative medicine.

Once there is more solid research backing these procedures, regenerative medicine should become more easily available and cost-effective for all patients.

From made-to-order organs to smart biomaterials that could help form functional tissues, the possibilities and future of regenerative medicine is endless. The NIH notes:

Imagine a world where there is no donor organ shortage, where victims of spinal cord injuries can walk, and where weakened hearts are replaced. This is the long-term promise of regenerative medicine, a rapidly developing field with the potential to transform the treatment of human disease through the development of innovative new therapies that offer a faster, more complete recovery with significantly fewer side effects or risk of complications.

Organizationslike the Stanford Medicine Institute for Stem Cell Biology and Regenerative Medicine and Mayo Clinics Center for Regenerative Medicine areat the forefront of researching new applications for regenerative medicine.

Many healthcare researchers today are grappling with the questions of what is regenerative medicine and what potential uses it can have for patients. To learn more about the future of regenerative medicine, check out the following articles:

Regenerative medicine clinics can be found in larger medical institutions like Mayo Clinic or Stanford Medicine, however there are also local doctors in your area who are running stem cell and regenerative medicine trials for their patients. Pain clinics, in particular, are offering regenerative therapies for conditions like arthritis and back pain.

You can find a pain clinic in your area by clicking the button below. The clinicsServices page will list which regenerative therapies they offer. Or, you can call their office and ask.

Originally posted here:
What Is Regenerative Medicine? - Pain Doctor

Read More...

False hope for autism in the stem-cell underground …

Thursday, April 25th, 2019

Scientific interest in stem cell therapies for autism began from one doctors observation.

In the late 1980s, Joanne Kurtzberg, a pediatrician specializing in blood cancers, worked with Hal Broxmeyer, who had been studying the stem cells present in blood from umbilical cords preserved at birth. Since the 1950s, doctors have treated blood cancers using transplants of bone marrow, which contains adult stem cells capable of generating blood cells. But as Broxmeyers group showed, cord-blood stem cells are more potent than adult stem cells at this task. Of particular value, they do not require a perfect match between donor and recipient.

Kurtzberg recognized the promise of cord blood for people of color, who often have trouble finding matching bone-marrow donors. So, in 1998, she founded the Carolinas Cord Blood Bank at Duke University and, in 2005, helped pass legislation to establish a national network of similar banks. Every year in the U.S., about 200,000 women donate cord blood from their babies to these public banks or to research labs; families also pay to store up to 7 million units of cord blood in private banks worldwide, though these samples rarely end up being used. In 2011, the FDA began requiring companies selling therapies developed from cord blood to submit data showing their safety and effectiveness.

In the late 1990s, Kurtzberg says she noticed something curious following cord blood transplants in children with certain metabolic conditions who also have autism traits. The transplants not only extended their lives but also seemed to prevent brain deterioration and improve brain function. Kurtzberg theorized that the stem cells in the cord blood might be engrafting in the brain and repairing damaged tissue. Other cells in the cord blood might also be sending chemical signals across the blood-brain barrier to lower inflammation, which is seen in some people with autism, she says.

To test the inflammation theory, Kurtzberg began collaborating with Geraldine Dawson, an autism researcher also at Duke. In 2014, they launched a clinical trial with $40 million in funding from the Marcus Foundation, a nonprofit based in Atlanta that supports a variety of causes. The foundations head, Home Depot co-founder Bernie Marcus, has called himself a real advocate for stem cells for autism, and he reportedly told the controversial leader of the Panama stem cell clinic the Perskins visited that he hoped to get approval from the FDA.

The Duke trial drew immediate criticism. In 2014, Arnold Kriegstein, a neural stem cell expert at the University of California, San Francisco, told Spectrum the study was a Hail Mary pass and that it was unlikely cord-blood stem cells could reverse autism-related changes to the brain during early development. None of their explanations hold water on why it would have any therapeutic value, Kriegstein now says. Paul Knoepfler, a researcher at the University of California, Davis who blogs about the stem cell industry, also expressed skepticism, noting that autisms causes are too diverse and mysterious for the therapy to make sense.

Still, the Duke team published encouraging results from the safety phase of the trial in 2017. Clinicians working with the researchers evaluated 22 of the participants, all between the ages of 2 and 5 years, and documented improvements in 13 of them six months after a single infusion. Without a control group, it is impossible to say whether the children would have improved anyway. A follow-up report found that those who improved showed increased connectivity in brain regions affected by autism, including the limbic system, but the researchers published no evidence to support their inflammation theory.

Because there were no adverse effects from the infusions, in November 2017 the FDA granted Kurtzberg special approval to provide cord blood infusions to certain children, including some with autism. Kurtzberg declined to say how much the treatments cost but confirmed that the parents from other countries are required to put down a $15,000 deposit; the money covers a 45-minute intravenous infusion of their childs own cord blood or that of a matched sibling. Kurtzberg says her team plans to treat about 1,000 children per year, and that they have a waiting list of more than a year. She expects to publish the results of a placebo-controlled phase of the trial sometime this year, comparing children who receive cord blood infusions with those who do not.

While the Duke trial pushes forward, others have sputtered. A 2018 clinical trial at the Sutter Institute of Medical Research in Sacramento, California, found minimal evidence of clinical effectiveness of cord blood infusions given to 29 autistic children. The National Institutes of Health clinical trials registry lists 11 other autism-related stem cell trials but 3 concluded years ago without registering any results, 3 are listed with an unknown status, and 2 have been withdrawn. Most are outside the U.S., and none randomized the participants to receive the therapy or placebo, which is considered the gold-standard approach in clinical trials. Some may even be pay-to-participate trials, which are little more than marketing ploys to lure customers, Turner says.

Kurtzberg acknowledges that her research has led to a boom in questionable stem cell providers but says her team members do their best to tell families to tread carefully. We dont want to promote a therapy thats not helpful, she says.

Excerpt from:
False hope for autism in the stem-cell underground ...

Read More...

About Us l Ophthalmology l University Hospitals l …

Thursday, April 25th, 2019

Under the direction of Douglas Rhee, MD, who is recognized as one of the nations leading glaucoma experts, University Hospitals Eye Institute delivers superior patient care, advanced clinical technology and pioneering research to seniors, adults and children from five centers of Excellence:

Patients, families and referring physicians benefit from convenient access to superior patient care, advanced clinical technology and pioneering research. We provide a full spectrum of ophthalmology services, including routine eye examinations, medical and surgical care for simple and complex vision disorders, inpatient consultations, diagnostic testing, and simple and complex adult and pediatric contact lens fittings.

At UH Eye Institute, we provide a variety of options because we understand that each person is different. Its why our nationally-renowned experts team up to design customized care plans tailored to meet the individual needs of our patients and their families.

Our physicians also work in partnership with the greater Cleveland community through volunteerism, committee memberships and service as board members and trustees. Our outreach includes Eversight, Cleveland Sight Center, Free Clinic (now Circle Health Services), Ohio Lions, and Prevent Blindness Ohio, which provides over 1,000 free eye exams per year to people without health insurance.

Link:
About Us l Ophthalmology l University Hospitals l ...

Read More...

Mark Armando Prendes MD Doctor Profile & Reviews …

Thursday, April 25th, 2019

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UHs policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Mark Armando Prendes did not disclose any Outside Relationships with Industry.

Go here to see the original:
Mark Armando Prendes MD Doctor Profile & Reviews ...

Read More...

Dry Eye Center | University Hospitals | Cleveland, OH …

Thursday, April 25th, 2019

The Dry Eye Center at University Hospitals Eye Institute offers unique treatments for patients suffering from dry eye disease. Our specialists are trained to treat patients using minimally invasive surgical techniques, as well as with a wide array at-home dry eye treatments and non-invasive therapies conveniently available to patients in our offices.

Our innovative optometrists and ophthalmologists have created the only dry eye center of excellence in the Cleveland area. Our providers are proud to offer a wealth of knowledge and treatments that are unique and effective. We are determined to ease our patient's dry eye symptoms and provide education on how to manage symptoms.

Our use of the Prokera Slim, an amniotic membrane, sets our program apart from other practices. View the video below to learn how Prokera Slim could cure you of your dry eye symptoms.

We take great pride in delivering compassionate and advanced care that is highly sensitive to our patients' individual needs by bringing together trained specialists, including:

To request more information, contact the Dry Eye Center at 216-844-3601.

Continue reading here:
Dry Eye Center | University Hospitals | Cleveland, OH ...

Read More...

Erik Moffat Ostler MD Doctor Profile & Reviews …

Thursday, April 25th, 2019

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UHs policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Erik Moffat Ostler did not disclose any Outside Relationships with Industry.

Read more here:
Erik Moffat Ostler MD Doctor Profile & Reviews ...

Read More...

Stem Cell Transplants For Incurable and Untreatable …

Wednesday, April 24th, 2019

BCRO fetal precursor cell transplantation, has been usedsuccessfully for 80+ years as treatment of many diseases

in documented over 5 millions of patients worldwide. Physicians can learn about it in a textbook by E. Michael Molnar, M.D.:Fetal Precursor Cell Transplantation, BCRO Fetal Precursor Cell Transplantation, published in 2014 by http://www.amazon.com On the same web site the general readership can find out all about it in the book by the same author: Treatment of Incurable and No Longer Treatable Diseases, published in January 2015, as well as in his autobiography: Diseases and Genocide are not Our Destiny. You can buy it as free reader download for PC as well as Kindle Book.

The syllabus on the use of BCRO fetal cell transplantation (BCRO FCT) and BCRO fetal brain cell transplantation as a treatment of incurable/ untreatable diseases of all organ systems (including that of central nervous system!):

1/ Genetic diseases: All of known ~4,500 genetic diseases all incurable/untreatable by current medicine (controlled by the Big Pharma) can be successfully treated by BCRO FCT!

Such a huge statement can be made despite that there is no sufficient proof of results of such treatment for many extremely, or very rare, genetic diseases. In my experience of 26 years, whenever I was asked to treat such patient, the result was a success (of various degree) in practically all of correctly(!) diagnosed patients.

However, it is mandatory that the BCRO FCT treatment be done as soon as the diagnosis is made, i.e. without any major delay. The later in life the patient gets the treatment, the lesser is the chance of success. This applies in particular to the diseases of central nervous system in children, where all BCRO FCT treatments must be completed before reaching the 4th year of life(!).

In 1994 I treated - by request of close friend/colleague and his wife - by BCRO FCT his 24 years old oligophrenic daughter, likewise very close to me. This colleague was a member of Board of Directors of IIBM in Moscow, so he knew that his daughter was way too old to get a positive result from FCT. I treated her twice. Both parents were convinced that their daughter, who is today 48 years old, was noticeably improved by FCTs.

In 2007 our well known Hong Kong colleague, professor of medical school in Vancouver, Canada, advised me about a local TV program, where a mother of 3 years old boy with CHARGE syndrome, a very rare genetic combination of anomalies, in particular deafness and blindness, was begging hospitals and physicians to help her son. I decided to give it a try for free although I did not know anything about CHARGE syndrome, except for the old adage (of mine): when there is nothing known about extremely rare genetic disease, there in nothing wrong with trying BCRO FCT, because it is so safe! After three FCTs about four months apart the success was exceptional, in particular the reversal of blindness and deafness. It was reported on the same Hong Kong local TV station.

Central nervous system is the sole system of the human body, the development of which is not completed until the end of 4th year of life, i.e. the diseases of central nervous system respond to the BCRO FCT very well until then, but the same cannot be expected later on.

Human being is the sole member of animal kingdom, completely unprepared to live independently up until one year of age, i.e. no Tarzan could survive alone in Nature during the first year of his life, without the nurturing of his mother, in this case the gorilla.

Our International Institute of Biological Medicine in Moscow, in existence from 1990 till 1997, carried out a clinical research in collaboration with a Russian Research Center of OB/GYN and Perinatology of RAMS, whereby all newborns with Apgar score 1 3, i.e. with miniscule capacity to survive and to develop as normal human beings, got CT scan of their brain at the age of 2 weeks (no MRI was available then) and if the classical radiological sign of peri-ventricular malacia was found, then at 6 weeks of life the first fetal brain cell transplantation of white matter of brain was carried out, even though no official neurological diagnosis could be obtained as yet. The same treatment was repeated in 4 months, and again in another 4 months, following which the clinical diagnosis was already possible to make, that explained the reason(s) for low Apgar score. Later on, after the age of 1 year, fetal cell transplants of other parts of the brain and other body organs were added, as needed.

If ethics of modern medicine demand a resuscitation of every newborn with a birth weight of 500 grams, and extraordinary intensive care to keep such newly born alive, then medicine and human society should also assure that such newborns get a chance to become more than just permanent wards of chronic care hospitals.

When facing a serious damage of brain, the earlier in life is BCRO FCT done, preferably immediately after the diagnosis is established, (even in utero!), the better will be the outcome, because BCRO FCT cannot repair scar tissue! At such an early age there is no need to transplant fetal brain cells directly into the brain (by intrathecal implantation), a standard implantation works well, because the homing, which delivers fetal cells of the brain where they belong, i.e. into the brain, even if implanted elsewhere in the body, for example under the skin, is most active(!) at that stage of human development.

In other words, in any case of brain damage caused by event in utero, or during birth, treatment by BCRO FCT should be carried out as soon as possible. Later on any such treatment is much less effective, and definitely so if done past the 4th year of life.

Once the child is diagnosed with a cerebral palsy after 4th year of life, BCRO FCT, or any other, will have a much diminished effect, if any. Parents of cerebral palsy children spend enormous amount of time and money seeking treatment at the time when it is already too late.

One such child born at Russian Research Center of Mother and Child of RAMS in Moscow, was diagnosed at the age of 9 months with a congenital deafness, but already at that age the hearing loss was diminished to 60%, thanks to fetal brain cell transplantation, as was done already at 6 weeks of life( !).

Such very early BCRO FCT treatments were exceptionally appeciated in cases, where the newborn was extremely wanted by the parents.

2/ Chromosomal diseases, such as Down syndrome, with an incidence of 1:500 of live births, the most common among chromosomal and genetic diseases, and its treatment by fetal cell transplantation, proved to the world that hopeless inborn childhood diseases can be helped by such treatment quite well. It was the tremendous work of Prof.Dr. Franz Schmid, of Germany, born in Czechoslovakia, as Sudeten-German, No.1 expert in cell therapy, until his death in 1997 (next after the official father of this treatment Prof.Dr. Paul Niehans).

Major West German statistics of 1950 1990s proved that fetal cell transplantation, following the rules described above under genetic diseases, did allow Down syndrome children to enter the regular German public schools, which are much more difficult, than the private ones, successfully finish 8 years course of studies, obtain a vocational education, which prepared them to get regular jobs, in at least 50% of instances.

Our IIBM in Moscow started its treatment with IIBM FCT in early December 1992 by starting with our first patient: 2 years old boy with Down syndrome (in honor of our Director Prof.Dr. F. Schmid). Right after, our first study was commenced, comparing two matched groups of Down syndrome patients, all 2 years old, one treated with FCT, and the second not treated. Of the second group 50 % of patients died within 8 months - before they reached the age of 3 years! This was the last comparative study ever for IIBM to do.

In 1993 came to us in Moscow a 4 years old girl from Puerto Rico, who was previously treated by German cell therapy by Prof.Dr. Schmid. Her father wanted to compare the results of our FCT with cell therapy. It happened that the patient was in Moscow at the same week as Mike Wallace of CBS 60 Minutes was doing his most valuable report about me and IIBM. Mike Wallace talked the father to let him to film his daughter: as usual he betrayed the trust of father, as he made fun of the patient and her father in his usual way.

The patient had very good result, so the family decided to have FCT No. 4 in 4 months.

When the patient was entering the school at the age of 6, the laws of Puerto Rico required the entrance exam by clinical psychologist. The father wrote me a letter, excited that the Ph.D. psychologist pronounced his daughter as normal and she entered the school for normal children. He added, that Mike Wallace better did not show his face ever in Puerto Rico, because he will learn how hospitable Puerto Ricans can be

The patient was lucky because her parents believed in FCT and started her treatment when she was 2 years old. These patients have only one real handicap, even after FCT: lack of abstract thinking, thus they will not become Albert Einsteins

There has been also a success in FCT treatment of Turner syndrome, Klinefelter syndrome, Angelman syndrome, Greig syndrome.

3/ Cerebral palsy has been successfully treated by BCRO FCT for years as long as treatment began prior to the age of 4 which was practically never!

With dyskinetic and ataxic CP children there is frequently a therapeutic success even if BCRO FCT is done even later, but not past the age of 10.

In hypotonic forms BCRO FCT treatment should be tried once, even if the patient is already past the age of 4, as there may be some therapeutic success, in which case additional treatment - every 4 months - should be done, as long there is appreciable positive result.

4/ Classical autism (Kanner autism, described in 1943) treatment by BCRO FCT was pioneered by myself, in 2007 in Hong Kong, where the colleague of mine, previously the professor of medical school in Vancouver, Canada, asked me to donate my time to give a consultation to the parents of a 9 years old boy with a classical autism. I was aware, that based on official teaching of all California physicians, the state in U.S. with the highest incidence of classical autism in the world, - where I was a practicing surgeon, I likewise was of the opinion, that classical autism is a psychiatric disease, and as such untreatable by FCT!

I met with parents of autistic boy, two highly educated young people, who devoted all their available time to learn everything that was known about autism. After their three hours long lecture, they convinced me that autism is not a psychiatric disease, and it is a result of measles-mumps-rubella vaccination, and thats why the incidence of classical autism was highest in California in the world, because 100% children there were vaccinated (and when they were not, they were not permitted to enter school) with MMR vaccine

I was willing to accept their explanation of mistake of official medicine, because I learned in my medical school in Czechoslovakia about an extensive research, done in Europe before WW2, about the mandatory vaccination against the measles of young men : the live attenuated vaccines were given to young men before drafted into the army, that measles gotten at the age of 18 20 caused large number of cases of encephalitis.

I saw their son, my first patient with classical autism ever, and it was a frightening sight: he almost destroyed the doctors office in 20 minutes despite being held by 3 bodyguards.

One month later I carried the BCRO FCT on their son, with help of 3 able bodied men and the father to hold him down. Two month later I saw the patient again. He was a completely different person, a calm, self-controlled, intelligent boy. He greeted me with polite handshake and kisses on both of my cheeks. The parents said that during two months post FCT he was upgraded two classes up in his private school. The school teaching staff spoke about a miracle. The parents did not tell anyone that their son had fetal cell transplantation.

I told immediately the organizers of my FCT scheduling to call back all parents of other autistic children, that I previously refused to treat, and inform them that I changed my opinion: now I do treat all classical autism patients with FCT. Every single patient with classical autism under age of 12 that received BCRO FCT lost all symptoms and signs of being autistic.

The therapeutic success has been 100% in all of 60 first patients treated. One problem remained: their education remained on the level of age, when they became autistic. It was mandatory to saturate the brains of all patients with all information, that they did not absorb while they were in autistic state.

One BCRO FCT treatment was sufficient in all patients.

Up until 12 years of age subcutaneous implantation of BCRO FCT has been used. - Over the age of 12 intrathecal implantation of BCRO FCT (via lumbar puncture) must be carried out, due to the closure of hemato-encephalic barrier, that usually becomes complete by the age of 12.

Classical autism is caused in all patients by MMR (measles, mumps, rubella) vaccine. Since in the State of California the MMR vaccination is mandatory and enforced by law ( the child is not allowed to enter the school with the legal consequences for the parents) the incidence of classical autism is 1:100!

A few years ago an artificial (and illogical) classification of autism spectrum disorders was made, which bears no relationship to reality. There are no autism spectrum disorders known in Nature.

BCRO FCT cannot be used to treat autism spectrum disorders, only classical autism patients as defined by Dr. Kanner.

5/ Aging disease has been at all times the most common reason for fetal cell transplantation therapy for 80+ years. According to the West German statistics of 1950 1990, of 5 million patients, who received such therapy in that country, about 4 million claimed that aging was the main reason for seeking such therapy, although many of them suffered from a variety of other medical conditions as well (besides menopause in women and impotence in men). FYI, 250.000 Americans travelled to West Germany or Switzerland for cell therapy, primarily for treatment of aging disease.

German patients considered their zellentherapie successful in 90% cases and desired a repetitive treatment at regular intervals. According to BundesGesundheitsAmt report one aging man received such therapy 27 years in a row (German method of preparing zelltherapeutica, which is less sophisticated than that of BCRO FCT, required once a year treatment).

With fast growing incidence of dementia, most commonly diagnosed as Alzheimers disease, the frequent component of aging disease is becoming the treatment of dementia by intrathecal BCRO fetal brain cells implantation via lumbar puncture, with exceptionally good results, even in the most advanced stage 4 of Alzheimers disease patients.

With BCRO FCT it is recommended that the treatment of aging be repeated every 3 years.

After the end of WW2 the post of West German Chancellor was offered to Konrad Adenauer, then 73 years old. To take the responsibility of leading the country completely destroyed by WW2 at that age was considered a super-human task. Yet the Chancellor Adenauer kept that job until he was 94, for 21 years(!) It was a common knowledge of all Germans, that he religiously set aside one week a year for his cell therapy treatment.

Charlie Chaplin married at the age of 57 a woman 30 years younger. He bought right away a villa next door to Prof.Dr. Niehans, the father of zellentherapie, to make sure that he would receive fetal cell transplantation every year. After the birth of child No. 8 Madame Chaplin paid a visit to their neighbor to beg him to stop giving her husband those cells because she is already tired. Charlie Chaplin finished his last film King in Hong Kong at the age of 84, in his usual way: he wrote the script, directed the movie, composed the music and played the main role.

Many kings and presidents of countries, famous personalities, etc., received such treatment between 1931 to this date. The partial list is available.

In 1985 the First Lady Nancy Reagan decided that her husband, President Reagan, must get the cell therapy. He just lived through Hinckleys assassination attempt plus was found to have a precancerous condition of colon. He was the oldest U.S. President to date. So she was absolutely right when she tried to help her husband by getting for him the very well known treatment, that worked. The ban by U.S. FDA of cell therapy since 1956 was not stopping her! Invited German physicians carried it out at Walter Reed Army General Hospital in Washington, D.C. That treatment helped President Reagan to successfully finish his two terms!

I learned about it during the annual meeting of selective German Society of Cell Therapy, that I was the only U.S. member of. My friend Prof.Dr. Schmid was a President.

In 1977 we became neighbors of Mr. and Mrs. Reagan. Their house was of mile from ours. They lived there for 30 years. Riviera was a very friendly, closed community: our neighbors gave a welcoming big party for us and they all to make us feel welcome. My wife was introduced to Mrs. Reagan by her best friend to this date, who was our neighbor. Her husband was a chief of Department of Surgery in nearby St. Johns Hospital, the best private hospital in L.A. then, where I had surgical privileges. I shared my chiropractor with past twice governor of California and future U.S. President. In honor of this relationship I broke my rule (that I made after the departure from communist Czechoslovakia) to never become politically engaged anywhere and joined the Republican Party. I still keep many honors - in memory of President Reagan and his First Lady. He was the only U.S. President that I really liked.

I started to take FCT every 3 years when I was 47. My last treatment was combined with fetal brain cell transplantation on 12/12/2016.

The goal of medicine should be not only to find out why aging disease takes place, but also discover therapy to preserve the vitality of aging organism for as many years to come as possible, perhaps until the limit of our life, which is allegedly 120 years.

Vitality measures an ability of ones organism to realize all vital functions in physical, mental and spiritual spheres. It is an optimal performance of capacities existing in an individual. The best time to start such treatment is at the age of 40.

6/Diabetes mellitus type 1 with complications:

Every patient with diabetes mellitus type 1, or juvenile diabetes mellitus, will with a guarantee - develop complications typical for this disease over the next 10 years, such as diabetic retinopathy, the most common reason for blindness (in U.S.), diabetic nephropathy, leading cause of kidney failure, requiring hemo-dialysis and eventually kidney transplantation, diabetic poly-neuropathy, causing in 90% of such patients untreatable pain in lower extremities, diabetic lower extremity arterial disease, with gangrene of legs, requiring amputation, brittle diabetes in children, which is a very serious condition(!) of fast development of diabetic complications, complications of pregnancy in diabetics, such as fetal death, and female infertility. In all such patients BCRO FCT is the sole(!) treatment for such problems, that works uniformly well every time.

USSR was the first country in the world that discovered that human FCT is the sole treatment of complications of type 1 diabetes mellitus in late 1970s, by Prof.Dr. Shumakov and his team at Research Institute of Transplantology and Artificial Organs of USSR Ministry of Health in Moscow, which led to the development of BCRO (animal) fetal cell transplantation in 1997.

In early 1993 our IIBM began to receive requests for FCT treatment from abroad. The first South Korean patient was a young music composer, author of anthem for Seoul Olympic Games, who suffered from a very advanced type 1 diabetes mellitus with serious complications. He was treated with FCT: he became insulin-independent(!), which means that he did not have to take any insulin for 5 months(!), and his health improved tremendously. He let to know about it the entire nation of South Koreans. Soon VIPs of that country were coming in drones to Moscow for FCT.

In 2007 in Peoples Republic of China, after several visits to Shanghai, Guangzhou, Suchow, with all day long lectures about BCRO FCT, I was invited to Beijing by the famous four star general T.Y., that was the No.2 man behind Marshall Yap as No. 1, (Marshall Yap was the No. 5 in the hierarchy, after the Chairman Mao), of the team given the task - by the Politburo of the Communist Party of China - to take care of worst problem that country ever had, the coup of the first wife of Mao Ze Dong with the gang of four, which almost destroyed that country. General T.Y. was the one who found Mr. Deng Xiaoping in the concentration camp, where he was kept locked up by the gang of four, and was instrumental in installing him as a leader and architect of new China, as we know it today.

Subsequently General T.Y. decided to get involved in the organization of BCRO fetal cell transplantation project in China.

He suffered from advanced untreatable disease (I dont have his permission to disclose his diagnosis). Before his FCT he requested a permission to get such treatment from the first secretary of Communist Party of China - in writing. Only after he was given such permission - in writing I received a green light for his BCRO FCT. It was done in improvised operating room of five star hotel, big enough for about 50+ guests, invited by him to observe his BCRO FCT, with two TV cameras to record it. I was assisted by four senior surgical nurses. This was the first BCRO FCT I did in China. - After that all remaining patients were from the same group.

My private medical consultations in China were done usually in front of audience of up to 100 people. I was told that the visitors consisted mostly of family members. I did up to 10 consultations at the time, of different family members. Son of General T.Y., who lived in California, U.S. citizen, was my translator and keeper of patients medical records.

One problem I had was that only Chinese was spoken. In the rest of the countries - on all five continents - I was able to understand the patients partially, though enough, to be able to establish the usual physician - patient relationship: my translator could not cope with the volume of information so that I could not get into the real relationship (meeting of minds) with the patients as I was accustomed.

That was the first time in my life where I had the opportunity to get the first hand information about the life of ruling class.

The second patient was a four star general, who was until his retirement 2 years ago, the chief of secret service of China for 22 years. He spoke Russian too so that I could speak to him without a translator. Prior to taking this post he had to be found hidden in one of the concentration camps, courtesy of gang of four and their leader: wife of Mao. He suffered from the medical problem, which could not be helped by FCT, but he wanted to give it a try anyway. The next patient was his wife.

And there were many others from the ruling class of China.

I learned interesting facts about Mao Ze Dong and the Chinese history, modern and past, which I did not learn in school even though I lived until May 1, 1969, in the communist Czechoslovakia.

IIBM was invited in 1993 by Sansum Medical Research Foundation, Santa Barbara, California, for cooperation and a treatment of patients with incurable/untreatable diabetes mellitus with diabetic retinopathy and nephropathy, and with Los Gatos Hospital. In U.S.A. we treated altogether 55 patients. There was a wide publicity in Los Angeles Times of this. (Read my https::/bio-cellular-research.com, Chapter I: Definition and Basics, part 3: History, under the heading: Bio-Cellular Research Organization, for details.)

Type 2 diabetes mellitus with diabetic complications(!) has been an indication for BCRO FCT, but the success is limited only(!) to cases of non-obese diabetics.

BCRO FCT has been a mandatory(!) treatment for children with brittle diabetes. It has to be done in a hurry, to prevent the much faster development of the usual diabetic complications. The pioneering work was done in USSR in 1980s in Kiev.

7/ Other endocrine diseases:

Pituitary nanismus was the first disease successfully treated in 35 children by animal fetal cell transplantation, already 100 years ago, by Prof.Dr. Niehans.

Various forms of hypothalamic syndromes have been treated successfully by FCT, such as Sheehan syndrome, anorexia neurosa, bulimia, morbid obesity, intractable diabetes insipidus.

Diseases of adrenal cortex, such as adreno-cortical insufficiency, Addisons disease, exhaustion of adrenal cortex by over-treatment of variety of diseases by cortisone, excessive use of cortisone in treatment of variety of diseases, without real indication, all these require timely BCRO FCT treatment.

Male infertility is the cause of infertility of a couple in 50% of instances(!). There is a successful treatment of this condition, the entire protocol is based on BCRO FCT, that could be carried out in most modern infertility clinic.

A young ophthalmologist, that was made by Prof.Dr. Fedorov a liason between the world famous Fedorov Eye Institute in Moscow and IIBM, was infertile. He asked me to be the first male to be able to father a child, despite the total lack of sperm. Along with Infertility Center of IIBMs minority partner, the huge Russian Center for Care of Mother and Child of RAMS, we developed the therapeutic method for male infertility. The young eye specialist was the first infertile male to have the son of his own. There were two more such lucky men in Moscow.

At IIBM we developed a technique, which could be used for infertile males. It required services of an infertility clinic. After a complete evaluation of the male patient the FCT was carried out. After a month the patients ejaculate must be collected every week for 4 weeks, and inspected for normal, mobile spermatozoa. If any are found, they have to be concentrated and saved by freezing. When a sufficient quantity of mobile spermatozoa is accumulated, an artificial insemination is carried out. These steps are repeated, if necessary.

As a male is usually not happy with the idea that the child of record would not be really his, before electing a sperm of the donor to be used for in-vitro-fertilization, a trial of above method is worthwhile.

Premature menopause has reached epidemic proportions in the modern world, full of young women that are overzealous in their competition with men, many with 36 known venereal diseases transmitted by unprotected sex.

One third of 170 such patients received hormonal therapy, which was unsuccessful, while the second third of patients got repeated (!) BCRO FCT treatment with dramatic improvement of all pertinent hormonal levels, and the last third received placebo only. Such therapeutic protocol was developed by International Institute of Biological Medicine in Moscow in 1993/4.

Untreatable endometriosis, and uterine myomas, can be successfully handled, without hysterectomy or more aggressive surgical procedures (in case of myomas), by BCRO FCT.

A 42 years old Chinese businesswoman wanted a first child, but was not getting pregnant. Her gynecologist found a huge myoma in her uterus, which most likely was the cause of her infertility. Then she heard from me, that BCRO FCT usually shrinks myomas. She received FCT, got pregnant soon thereafter, married the father of her baby and became a happy mother of little boy.

Intractable chronic prostatitis with impotence has been successfully treated with by fetal cell transplantation and demanded loudly by wives of Soviet Navy men, loudly complaining to commanding admiral of the fleet about sexual non-performance of their husbands.

The rest is here:
Stem Cell Transplants For Incurable and Untreatable ...

Read More...

Stem Cell Therapy – Regenerative Health Centers of Florida

Wednesday, April 24th, 2019

Leading Stem Cell Therapy in Florida

The human body is built to heal itself. If youve experienced an injury or other chronic condition that has left you with pain, you have options. Stem cell therapy repairs damaged tissue in your body to restore your health. You can finally live a life free from pain!

While there are many sources of stem cells, Regenerative Health Centers of Florida uses cells harvested from umbilical cords. These cells are grown into specialized cells to help with muscle, ligaments, cartilage, nerves, and more. Specialized stem cells are injected into problem areas through a quick procedure. The stem cells then grow and repair within the affected area, delivering lasting results.

You dont have to live with chronic pain. Stem cells are a successful and safe way to treat a variety of conditions and injuries. Under the leadership of Dr. Michael Lampe and Dr. Jana Lampe, Regenerative Health Centers of Florida has helped people relieve their pain and heal injuries!

Using a quick and proven process, stem cell therapy delivers results that heal your body permanently. Contact the specialists at Regenerative Health Centers of Florida today to explore if this treatment is right for you.

Nobody should have to live their life with pain. If youre suffering from chronic pain or injuries,stem cell therapymight be the right treatment for you. We focus on the patient experience at every step of the way at Regenerative Centers of Florida. We know how frustrating it is to try treatment and medication with no success. You just want something that actually works for you.

We offer next generation healthcare. We offer long-term pain relief without relying on harsh surgery or a lifetime of medication. Regenerative therapy is natural, and it uses your bodys own healing powers to solve even complex pain problems.

Stem cell therapy is risk-free with no reported negative side effects. Not only is the treatment fast and painless, but youll be on your way to lasting relief in just a few weeks. The results of stem cell therapy last a lifetime since they heal your body from the inside out. That means no more complicated procedures, and no more living your life with pain. This is the treatment youve been waiting for! See our services below to explore the best option for you.

Stem Cell Therapy

Stem cells treat a number of injuries and conditions. Stem cells are unspecialized cells which divide to repair and replace damaged tissue, cartilage, ligaments, and even nerves. They grow into only what is needed, meaning your body can regrow healthy tissue naturally. Stem cell therapy is a quick procedure with practically zero recovery time!Click here to learn more about stem cell therapy.

The rest is here:
Stem Cell Therapy - Regenerative Health Centers of Florida

Read More...

Stem Cell Therapy New York | Stem Cell Treatment …

Wednesday, April 24th, 2019

Stem cell therapy uses a patients own stem cells to treat minor to moderate conditions formally where surgery would be the primary option. Stem cell therapy is an alternative to surgery through an office based procedure. Through advanced technology stem cell therapy is now a quick and easy alternative to surgery.

What are stem cells?

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as of internal repair system, dividing essentially without limit to replenish other cells. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Regenerative Growth FactorsStem cells have high natural growth factors that promote healing. These growth factors also naturally decrease inflammation.

Patients stem cells are obtained from their pelvic (hip) bone. The practitioner then concentrates the stem cells over 10 fold in a special centrifuge.

This office based procedure takes 30 minutes. Patients can leave at the conclusion of the procedure.

A local anesthetic is used. This results in minimal discomfort.

There have been numerous clinical studies that show significant and lasting reduction in pain for a variety of injuries. Common injuries include early to advanced arthritis, knee and shoulder pain.

Multiple clinical studies have shown that when effective, the results last many years.

Yes see the article section

85% of patients experience a benefited result from treatment

Most patients feel no improvement for at least 3 weeks and possible 6-8 weeks. Once you feel improvement, you will notice continued improvement expanding over 6 months.

Go here to see the original:
Stem Cell Therapy New York | Stem Cell Treatment ...

Read More...

Gene therapy might be a cure for "bubble boy disease …

Tuesday, April 23rd, 2019

They were born without a working germ-fighting system, every infection a threat to their lives. Now eight babies with "bubble boy disease" have had it fixed by a gene therapy made from one of the immune system's worst enemies HIV, the virus that causes AIDS.

Astudyout Wednesday details how scientists turned this enemy virus into a savior, altering it so it couldn't cause disease and then using it to deliver a gene the boys lacked.

"This therapy has cured the patients," although it will take more time to see if it's a permanent fix, said Dr. Ewelina Mamcarz, one of the study leaders at St. Jude Children's Research Hospital in Memphis.

Omarion Jordan, who turns 1 later this month, had the therapy in December to treat severe combined immunodeficiency syndrome, or SCID.

"For a long time we didn't know what was wrong with him. He just kept getting these infections," said his mother, Kristin Simpson. Learning that he had SCID "was just heartbreaking ... I didn't know what was going to happen to him."

Omarion now has a normal immune system. "He's like a normal, healthy baby," Simpson said. "I think it's amazing."

Study results were published by the New England Journal of Medicine. The treatment was pioneered by a St. Jude doctor who recently died, Brian Sorrentino.

SCID is caused by a genetic flaw that keeps the bone marrow from making effective versions of blood cells that comprise the immune system. It affects 1 in 200,000 newborns, almost exclusively males. Without treatment, it often kills in the first year or two of life.

"A simple infection like the common cold could be fatal," Mamcarz said.

The nickname "bubble boy disease" comes from a famous case in the 1970s a Texas boy who lived for 12 years in a protective plastic bubble to isolate him from germs. A bone marrow transplant from a genetically matched sibling can cure SCID, but most people lack a suitable donor. Transplants also are medically risky the Texas boy died after one.

Doctors think gene therapy could be a solution. It involves removing some of a patient's blood cells, using the modified HIV to insert the missing gene, and returning the cells through an IV. Before getting their cells back, patients are given a drug to destroy some of their marrow so the modified cells have more room to grow.

When doctors first tried it 20 years ago, the treatment had unintended effects on other genes, and some patients later developed leukemia. The new therapy has safeguards to lower that risk.

A small study of older children suggested it was safe. The new study tried it in infants, and doctors are reporting on the first eight who were treated at St. Jude and at UCSF Benioff Children's Hospital San Francisco.

Within a few months, normal levels of healthy immune system cells developed in seven boys. The eighth needed a second dose of gene therapy but now is well, too. Six to 24 months after treatment, all eight are making all the cell types needed to fight infections, and some have successfully received vaccines to further boost their immunity to disease.

No serious or lasting side effects occurred.

Omarion is the 10th boy treated in the study, which is ongoing. It's sponsored by the American Lebanese Syrian Associated Charities, the California Institute of Regenerative Medicine, the Assisi Foundation of Memphis and the federal government.

"So far it really looks good," but patients will have to be studied to see if the results last, said Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, which helped develop the treatment. "To me, this looks promising."

Rights to it have been licensed by St. Jude to Mustang Bio. Doctors say they have no estimate on what it might cost if it does become an approved treatment.

A similar technique harnessing a modified version of HIV is also being studied as a possible cure for sickle cell anemia, CBS News chief medical correspondent Dr. Jon LaPook reports. In a clinical trial at the National Institutes of Health, nine adults with sickle cell anemia have undergone the gene therapy. So far, all are responding well.

Continue reading here:
Gene therapy might be a cure for "bubble boy disease ...

Read More...

Page 11234..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick